In efforts to combat the ongoing opioid crisis in America, the US House of Representatives is currently working to push through dozens of bills that many believe could help curb the rising overdose death rates and give the country a fighting chance. However, some have pointed out that Big Pharma MAT drug makers are spending millions lobbying Congress, and those same companies stand to bank big money off these new laws.
So, while we want to believe that new laws supporting Medication Assisted Treatment or “MAT” could help with harm reduction efforts, it is also good to point out that the drug companies who are positioned to benefit substantially are also those who have been racking up a lot of influence in Washington through huge donations.
In just a two week period, the House has already cleared several measures that would soon launch these MAT drug manufacturers into a sales spike.
Top MAT Drug Makers Lobbying Congress
So how much are these Big Pharma companies spending?
This biopharmaceutical company focusing mainly on central nervous system disease has already spent $1 million in lobbying. Part of that money went to support a bill that would fund full-service centers where people can:
This MAT drug maker is poised to cash in on this law because it could bolster the sales of anti-addiction injection Vivitrol. This is currently Alkermes best-selling product. However, the need for patients to fully detox before taking the drug is a limitation.
The aggressive marketing tactics this company is using, on top of their big budget for trying to influence Washington is already gaining them some attention. One thing that draws some of that attention is that the main focus of Alkermes lobbying was the bill presented by Representatives Brett Guthrie and Gene Green. Coincidentally, one of Alkermes main lobbyists served as Guthrie’s chief of staff, and another was Green’s former legislative director. Yet another example of people working in Congress making a jump to rallying government officials behind drug companies.
Guthrie and Green both reject any implication that they drafted the bill to support Alkermes. It is true that by several MAT drug makers also support their proposal.
This UK based specialty pharmaceutical company spent $180,000 on lobbying Congress. Indivior’s money went to support a bill easing restrictions on certain controlled substances used in injectable anti-opioid treatments.
Indivior rivals Vivitrol with their own product, Sublocade. This anti-addiction treatment is a once-a-month injection to fight opioid cravings. The bill they are bidding for would make it much easier for doctors to buy Sublocade for addiction treatment.
Sublocade was approved back in 2017 as an extended release buprenorphine compound. It became the first once-monthly injectable buprenorphine formulation for treating opioid use disorder (OUD).
Braburn Pharmaceuticals is an MAT drug maker from Pennsylvania that dropped a cool $100,000 along with Indivior to support the same bill for easing restrictions on controlled substances.
Braeburn is also developing a competing injectable MAT drug. But back in January, the FDA sent a complete response letter to the company. In the letter the FDA requests more data to be compiled for the therapy. The product was previously recommended for approval by the FDA’s Psychopharmacologic Drugs Advisory Committee in November 2017.
As of May 2018, Braeburn announced Phase 3 of testing on CAM2038- the buprenorphine weekly and monthly injectable- had some positive developments. The results we published online in the Journal of the American Medical Association (JAMA) Internal Medicine.
If this MAT drug does get approval, it will be the first and only injectable opioid use treatment that healthcare professionals can administer from Day 1 of patient’s treatment.
But let us not forget that each of these injectable MAT drug treatments says they should only be a part of a complete treatment program that includes counseling and psychological support.
Big Pharma Supergroup
That may not be the actual name, but it is essentially what we are talking about. A group of non-opioid pain relief drug makers has also spent hundreds of thousands of dollars on lobbying. This Big Pharma “supergroup” aims to push for legislation that will allow for additional Medicare payment for non-opioid pain drugs. One such drug company is Heron Therapeutics out of California.
Heron alone spent $40,000 from January to March lobbying on the issue of setting rates for post-surgical non-opioid drugs.
Pros and Cons
None of this is to say the MAT drug makers should not support more options for addiction treatment. There should always be support for establishing more comprehensive and inclusive treatment opportunities. In the midst of one of the most devastating drug epidemics in American history, every little bit counts. MAT programs and harm reduction can save a life and give someone an opportunity to get treatment.
But we should also be aware of how much money any drug maker is pouring into the political system in hopes of greasing the wheels of the legislative branch. When the opioid crisis became a major campaign issue, Congress used February’s budget deal to authorize $6 billion in spending to address the epidemic. That is what suddenly inspired over 300 drug companies and interest groups to rush to Capitol Hill and lobby.
Overall, the House package is something that many anti-addiction advocates and other lawmakers see as only minor progress toward addressing such a massive public health crisis. Most agree that it is important to take what steps you can. Still, many agree these efforts fall far too short of what is truly necessary in order to make an impact.
These proposals can be a good step in the right direction. MAT drug programs can be useful in giving people a chance at getting off illicit drugs. However, MAT is only one element to treatment. It is not a sustainable substitute. Hopefully, more energy and funding in the future will help create detox and treatment expansion programs. Then more people can get the help they need instead of depending on drug companies to provide them with a temporary solution to such a complex issue.
Palm Partners Recovery Center believes in providing personalized and holistic treatment options. That is why we also offer MAT programs for those in need. Recovery is never one-size-fits-all, and we strive to help each individual find the recovery plan that is right for them. If you or someone you love is struggling, please call toll-free now. We want to help.
CALL NOW 1-800-951-6135
For most, there is little doubt that the War on Drugs is an indisputable failure. It has taken an excessive amount of money, manpower, and lives with little to show for it besides one of the worst drug epidemics in the history of the country. Time has proven these policies to be ineffective and costly, so where do we go from here?
Perspective in our nation changes and the stigma attached to addiction is now being to be confronted. Along with it all comes waves of new proposals on how America’s drug policies can evolve. Which is the right way is still unclear.
Right now, while many are confused if Jeff Sessions and the Trump administration will be actively cracking down on marijuana in states with legalization laws, there are others on the federal level that are actively pushing in the opposite direction. Part of a new bill currently in the House is trying to do even more to end the War on Drugs, by directly pushing pro-pot politics.
The Marijuana Justice Act
Last August, Democratic Senator Cory Booker from New Jersey introduced the “Marijuana Justice Act of 2017”. He was joined by Democratic Representative Barbara Lee from California in bringing the reform legislation to both chambers of Congress. Historically, this was the first time a companion legislation was introduced in both chambers to remove marijuana from the Controlled Substances Act (CSA). According to early reports, as a companion to Booker’s S. 1689 is the companion bill HR 4815. These efforts are to:
- Remove marijuana from CSA
- Incentivize states to mitigate existing and ongoing racial disparities in state-level marijuana arrests
- Expunge federal convictions specific to marijuana possession
- Allow individuals currently in federal prison for marijuana-related violations to petition for resentencing
- Create community reinvestment fund to invest in communities most impacted by the War on Drugs
Currently, marijuana is in the same federal category as drugs like:
Even those who do not advocate for marijuana legalization at least see the fault in its scheduling. Trey Growdy, the Republican Representative from South Carolina has repeatedly questioned why marijuana is considered a schedule 1 drug. This schedule actually puts it above Cocaine and methamphetamines.
One of the big pieces of the bill is also that bit about expunging convictions. Justin Strekal, political director for NORML (the National Organization for the Reform of Marijuana Laws) notes that this is “the first piece of legislation that addresses expungement issues,” to clean up former criminal records for cannabis use.
Now, a new version of the bill has been introduced to the House just last week. The goal is described as a campaign against the current federal drug policy and the failed War on Drugs.
Speaking with Sponsors of Bill
Last year, after introducing his version of the bill, Senator Cory Booker stated,
“Our country’s drug laws are badly broken and need to be fixed.”
“They don’t make our communities any safer—instead they divert critical resources from fighting violent crimes, tear families apart, unfairly impact low-income communities and communities of color, and waste billions in taxpayer dollars each year.”
Booker also believes getting rid of old pot-policies of the War on Drugs would help to bolster the economy. He states,
“It’s estimated that legal cannabis in the U.S. would create $40 billion in revenue and nearly a million jobs.”
“But it’s about more than that $40 billion —it’s about equality, and getting rid of the legal past that is stifling individuals’ opportunity and their future.”
One co-sponsor for the bill is Representative Ro Khanna. He says that revenue from taxes on marijuana would then be allocated to funding the programs to reinvest in communities that were harmed by the anti-pot policies of the War on Drugs.
Representative Barbara Lee says,
“This legislation will end this destructive War on Drugs.”
This new bill to attack the War on Drugs also has the support of the Drug Policy Alliance. Kassandra Frederique, the New York States Director for the Drug Policy Alliance, states,
“This bill makes clear to state and local elected officials that they cannot move forward beyond prohibition without taking a serious look at the historical and ongoing impacts of drug war policies.”
Supporters of the bill continue to emphasize that this isn’t just about ending pot prohibition. They say it is also about putting forth resources to help communities recover.
Why are We Talking About This?
As a provider of innovative holistic treatment for drug and alcohol abuse, we pay attention to the way drug policy changes because we know how it impacts communities around the country. In order to provide help to those who need it, we have to be talking about these changes. If drug policies shift, we must talk about how they can affect those who struggle with substance use disorder.
It does not matter if a drug is an illicit black-market substance, or a popular legalized product, substance abuse and addiction are still possible. If marijuana reform is going to continue to grow, it is also our responsibility to bring attention to the possible risks and side effects for some who use marijuana.
If pro-pot politics are going to put marijuana in the mainstream, there should also be an effort to promote substance abuse treatment options. Looking back, if the War on Drugs taught us anything, it is that there should be a strong focus on providing treatment, not punishment. If we want to make things better, we have to offer every opportunity to help those who need it most.
Marijuana abuse can have a noticeable impact on some people’s lives, and often times it is accompanied by another form of substance abuse. Acknowledging the influence of drugs in your life and knowing when to get help can make the recovery process a life-changing journey. If you or someone you love is struggling with substance abuse or addiction, please call toll-free now. We want to help.
CALL NOW 1-800-951-6135
Author: Justin Mckibben
The elections held this past Tuesday may not have directly addressed the status of marijuana, but voters in multiple states did elect officials who are adamant about making legal marijuana more available.
Next Year in New Jersey
One of those states is New Jersey, who’s outgoing governor is Chris Christie, chairman of the White House commission on opioids.
Last week Democrat Phil Murphy, who made legal marijuana one of the cornerstones of his campaign, won the state over. This creates a radical change for the state. For years Chris Christie has blocked attempts to legalize cannabis, and even maintains his opposition to it while fighting to help the country get a grip on the opioid epidemic.
Phil Murphy has been pretty open about his support for marijuana legalization. According to Forbes, Murphy even talked about it during his primary night victory speech saying,
“The criminalization of marijuana has only served to clog our courts and cloud people’s futures, so we will legalize marijuana,”
“And while there are financial benefits, this is overwhelmingly about doing what is right and just.”
Apparently, it isn’t just Murphy in the state that is looking forward to pushing this legislation along. The Democratically-controlled state Senate is expecting to bring up legal marijuana as early as next year. In regards to the topic, earlier this year Senate President Stephen Sweeney said,
“We are going to have a new governor in January 2018. As soon as the governor gets situated we are all here and we intend to move quickly on it.”
Voters in Virginia
Voters in the Commonwealth of Virginia also elected an official who advocates for loosening restrictions on marijuana. Current lieutenant governor Ralph Northam is in favor of decriminalizing marijuana possession. While it may not be as liberal a stance as Murphy, it is still a big step in a lot of people’s minds. Northam writes,
“We need to change sentencing laws that disproportionately hurt people of color. One of the best ways to do this is to decriminalize marijuana. African Americans are 2.8 times more likely to be arrested for marijuana possession in Virginia.”
But it isn’t just about the individuals. Northam also points out the resources going to this issue. He has written to the Virginia State Crime Commission as part of its review of the effects of marijuana decriminalization.
“Virginia spends $67 million on marijuana enforcement—enough to open up another 13,000 pre-K spots for children,”
Again, not that he is pushing for complete legalization, but to stop stiff penalties for those with small amounts of marijuana. Northam also advocates for research into the medicinal uses of marijuana. According to Richmond Times-Dispatch, he has stated,
“As a doctor, I like to make the point to people, over 100 of the medicines that we use on a daily basis come from plants,” he said in an interview Monday. “So I think we need to be open-minded about using marijuana for medical purposes.”
He isn’t alone in Virginia either. Even the Republican state Senate leader Thomas K. Norment Jr. questioned whether or not small amounts of marijuana should remain a crime.
Marijuana in More Areas
But it isn’t just these two offices that indicate there may be more change coming for marijuana policy. In other areas around the country, there are other notable shifts that may dramatically impact marijuana policy.
77% of voters in the college town eliminated fines and court costs for possessing or growing up to 200 grams of marijuana.
In an area that includes Detroit, voters now allow cannabis businesses to operate in more areas and to stay open longer. Michigan is expected to have a marijuana legalization bill on the 2018 ballot.
Lawrence Krasner won the election for District Attorney. Krasner has been outspoken about the benefits of marijuana reform. According to Krasner,
“One of the things we see in other jurisdictions is that, where marijuana is readily available, there’s a 25% reduction in opiate/opioid overdose deaths.”
“So if Philadelphia is looking at 500 opiate/opioid overdose deaths a year, a district attorney, by choosing not to enforce against marijuana usage, can potentially save 125 lives. That’s what a district attorney should exercise his or her discretion to do.”
It seems between lightening the punishments for possession, expanding programs for legal marijuana, and electing officials that will advocate for its use, marijuana may have already seen some real change this November.
What to Remember about Legal Marijuana
It is important to note for anyone who has a history of substance use disorder that the legal status of a substance does not make it safer. You could argue that marijuana is much safer than opioids like prescription drugs or heroin. While marijuana is not as lethal concerning overdose deaths, it still should not ignore the risks.
Marijuana reform has the potential for some positive and negative outcomes. Ultimately voters will have to consider weighing the pros and cons of reform. Either way, it is important to remember that any substance, legal or not, can be addictive. While marijuana may become more accepted on a legal level, it is still unhealthy to abuse this drug. If you find yourself abusing this or any drug it is very important that you seek safe and effective treatment resources.
Because drug abuse is always destructive, marijuana abuse is no exception. If you or someone you love are struggling with substance abuse or addiction, please seek help. Regardless of whether a drug is legalized or not, losing control of your use can lead to something much worse. We want to help. You are not alone. Call toll-free now.
CALL NOW 1-800-951-6135
Author: Justin Mckibben
The Global Commission on Drug Policy (GCDP) is an international institution of global leaders and intellectuals working to help study and inform initiatives on addressing drug use all around the world. This think tank offers recommendations concerning drug use and its consequences for societies across the globe.
The GCDP consists of members from various nations, including but not limited to:
- The United States of America
- The United Kingdom
Former U.S. President Jimmy Carter wrote an op-ed in The New York Times explicitly endorsing the recommendations of the Global Commission on Drug Policy, and the group has released various reports over the years focusing on the efforts to curb the spread of drug abuse.
Recently the GCDP released a position report on the North American opioid epidemic. In this report, the commission issues recommendations that appear to endorse the expansion of harm reduction techniques to battle the ongoing crisis.
The Turning Point for America
According to the GCDP’s new report, North America is at a turning point in the way that drug addiction is viewed. This is not too much of a surprise, considering now more than ever there has been a push for a more compassionate perspective on drug use and addiction. America now finds itself in a unique position where the stigma that has so long been attached to addiction is starting to be abandoned, and more progressive action is being taken.
Now the Global Commission on Drug Policy believes national policymakers should take advantage of this unique opportunity to reduce opioid-related deaths through harm reduction. In the report the authors state:
“While in recent years media and politicians have been more open to viewing addiction as a public health problem, leadership is needed to turn this into an urgent and commensurate response to the crisis,”
One way that the Global Commission on Drug Policy ideals clashes with that of the Trump administration, currently steering drug policy in America is that the GCDP does not endorse the old policies of the War on Drugs.
GCDP vs War on Drugs
Back in June of 2011, the GCDP stated:
“The global war on drugs has failed, with devastating consequences for individuals and societies around the world.”
Again, this recent report echoes that sentiment, saying that attempting to cut off the opioid supply is not the answer. The new report notes how this approach has been tried before, as the first reactions to the opioid epidemic were to limit prescriptions and to introduce pills that were harder to manipulate.
The report goes on to note that this response drove people to use cheaper and often much more potent street drugs instead of prescription pills. Fentanyl is one of the worst synthetic opioids to contribute to the outbreak of overdoses and deaths across the country.
The Global Commission on Drug Policy says cutting off the supply of opioids into the country cannot be effectively executed until after supportive measures are put in place. This means supporting not only both people battling addiction but also people with chronic pain. The report insists:
“The aim is to achieve the right balance in regulation to provide effective and adequate pain care, while minimizing opportunities for misuse of these medications.”
To reduce the harmful impacts of opioids, the commission calling for the acceptance and implementation of harm reduction strategies.
The Global Commission on Drug Policy Suggests Harm Reduction
So if they are saying that the War on Drugs did not work, and neither will bulking up borders, then what will?
Well, according to the GCDP, harm reduction is the right move. The new report calls on American lawmakers to promote programs like:
Naloxone Distribution and Training
As the opioid overdose antidote, Naloxone is an invaluable tool to have in the fight against the opioid epidemic in America, but the price for the drug continued to skyrocket as the epidemic got worse. Making it more available could give access to and train people with life-saving medication to thousands or even millions more.
Safe locations where IV drug users can trade old, contaminated needles for new, sterile needles to help prevent the spread of blood-borne illness like HIV.
Facilities where drug users can go to use their drugs with sterile equipment safely, reducing the number of overdose deaths by providing a place free of punishment for them to use with medical emergency resources on site.
These kinds of programs would allow for users to check their drugs for the presence of any unknown substances it may have been diluted with. For example, most fentanyl users do not know they are using fentanyl.
Decriminalizing Drugs in America
In another aspect of the report, GCDP also makes a much more revolutionary and more radical suggestion that many may consider qualifying as harm reduction: decriminalization.
The report states:
“The Global Commission on Drug Policy also calls for the elimination of illicit drug markets by carefully regulating different drugs according to their potential harms. The most effective way to reduce the extensive harms of the global drug prohibition regime and advance the goals of public health and safety is to get drugs under control through responsible legal regulation.”
With this philosophy in mind, the GCDP made two more drastic recommendations:
- End the criminalization and incarceration of people who use drugs nation-wide in Canada and the United States.
- Allow and promote pilot projects for the responsible legal regulation of currently illicit drugs including opioids.
The idea is that by decriminalizing drugs, they can bypass criminal organizations and ultimately replace the current black market.
“Do not pursue such offenses so that people in need of health and social services can access them freely, easily, and without fear of legal coercion,”
We have begun to see a watered-down variation of this kind of strategy with many Police Assisted Addiction and Recovery Initiative (PAARI) programs, where law enforcement is helping addicts get into treatment instead of arresting them when they ask for help.
Better Treatment Research
The report insists that more research is necessary in a few critical areas in order the effectively address the opioid crisis and the overall drug problem in America.
One of the key points of research the GCDP proposes is for finding the most effective treatments for addiction, specifically to prescription opioids. In addition, the report shows support for medication-assisted treatment (MAT) and opioid substitution therapy (OST) as a means to preserve life to assist in the recovery process. While these programs are met with some of the same contentions as safe injection sites or decriminalization, the commission seems adamant about using harm reduction to keep people alive long enough to get better.
Michel Kazatchkine, a doctor and commission member, said in a recent interview:
“Repression is harmful. Wherever repressive policies are in place, people will not be in the best condition to access services.”
While he and other commission members are in no way naïve to the fact there is no way decriminalization will happen at the federal level soon in the U.S., they remain hopeful that states or cities will make decisions which don’t require federal approval, or for which they are willing to enter to fight with the federal process.
Overall, the hope of the GCDP is that these suggestions, coming from a group of world leaders fully invested in understanding the issue, will convince American and Canadian lawmakers to take a progressive approach to the crisis.
What could some of these changes mean for those trying to recover from opioid abuse? How could some of these ideas change the way addiction treatment operates within America?
One thing is for certain, in fighting opioid addiction, whether as a society, as a family or as an individual, there needs to be compassion and action. It takes courage and it takes a degree of uncertainty. But with the right resources, there is hope for a greater future. If you or someone you love is struggling with substance abuse or addiction, please call toll-free now.
CALL NOW 1-800-951-6135
Californians expecting to get their marijuana delivered via drone should not hold their breath. A new set of regulations will make it harder for California businesses who try to deliver pot in unique ways.
The legalization of marijuana has raised a host of controversy. For one, the question of who has the right to distribute pot is already a complex issue. However, now there is the question of how these products get delivered.
Pot Drones? Should they be allowed?
California legislators are hoping to get these questions answered before issuing dispensary licenses next year. They came together this month to lay down the rules. Ultimately, it was decided that marijuana could NOT be delivered by drones.
The decision was part of the Commercial Cannabis Business Licensing Program Regulations released by the state.
“Transportation may not be done by aircraft, watercraft, rail, drones, human-powered vehicles, or unmanned vehicles,” the regulations read, according to Ars Technica.
While deliveries will be allowed, they must adhere to the following guidelines:
“Deliveries may be made only in person by enclosed motor vehicle. Cannabis goods may not be visible to the public during deliveries. Cannabis goods may not be left in an unattended motor vehicle unless the vehicle has an active alarm system. Vehicles used for delivery must have a dedicated, active GPS device that enables the dispensary to identify the geographic location of the vehicle during delivery.”
The news will be a major disappointment to the handful of businesses in California who already promised future pot deliveries by drone. One company, MDelivers, said the opportunity to deliver marijuana via drone was “unmistakable.”
Nevertheless, the company CEO did not count on lawmakers forbidding drone deliveries:
“After navigating the complexities of medical marijuana permitting, the state and FAA licensing process was actually pretty simple. Nobody can jump in at the 11th hour and rewrite the laws of aerodynamics,” Chris Boudreau, CEO and founder of MDelivers said in a blog post before the regulations were announced.
With the new policies in place, there is no telling how entrepreneurs will get marijuana to their customers. Even if drones are off the table, there are a variety of other new, interesting methods being considered.
“We may see a vending machine attached to a self-driving car before we see a drone,” Marshall Hayner, CEO of Trees Delivery, told Mashable.
As California prepares to expand its cannabis market, there continues to be challenges among those against marijuana legalization, especially when it comes to the products crossing state lines illegally. This has already been a major concern for states where port had been legal for recreational use such as Colorado and Oregon.
Surrounding states are trying to address the marijuana diversion issue by requiring pot businesses to track their product from “seed to store.” Time will tell how these sorts of issues will be regulated.
Furthermore, there remains to be conflicting ideologies on whether or not marijuana use is beneficials. While there has been proven benefits of marijuana use, there are also negative effects of marijuana use. Like any drug, marijuana has the potential to be abused.
As more and more states legalize marijuana, logistical challenges remain such as how the products can be delivered. Marijuana remains illegal under federal law, where it’s still classified as a controlled substance. This results in a variety of challenges in states like Colorado where recreational marijuana is legal.
The federal government requires that Colorado and any state that legalizes marijuana work together to prevent:
- Distribution of marijuana to minors.
- Transporting marijuana from states where it’s legal to other states.
- Growing marijuana on public lands.
- Marijuana possession or use on federal property.
- Other criminal activity or violence associated with the sale of marijuana.
It is important to remember that like any drug, marijuana has the potential to be abused. Do not feel shame for feeling out of control of your marijuana use. Stigma should not prevent you from seeking treatment. If you or someone you know is struggling with substance abuse, please reach out today. Do not wait. Call toll-free now.
CALL NOW 1-800-951-6135